NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
02/26/02	€0.8700	+0.58%	4,973
01/26/01	€0.8650	-0.57%	47,799
30/26/30	€0.8700	-0.11%	24,106
29/26/29	€0.8710	+3.69%	50,736
26/26/26	€0.8400	-1.18%	7,372

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 09:25:00 02/07/2026 pm IST			5-day change	1st Jan Change
0.8700 ^EUR	+0.58%		+2.35%	-26.15%

30/06	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
30/06	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation

Market Cap	1.1Cr 1.26Cr 1.01Cr 94.41L 1.79Cr 120.12Cr 1.82Cr 12Cr 4.72Cr 59Cr 4.74Cr 4.63Cr 203.01Cr	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	94.05L 1.08Cr 86.37L 80.54L 1.53Cr 102.47Cr 1.55Cr 10Cr 4.03Cr 50Cr 4.04Cr 3.95Cr 173.19Cr	EV / Sales 2024	3,70,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

30/06	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
30/06	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
02/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
01/06	NFL Biosciences validates breakthrough in personalized medicine
26/05	Glimmers of hope for Middle East peace grow brighter
26/05	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
25/05	NFL Biosciences files new patent application
25/05	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
12/05	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
04/05	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
16/04	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	NFL Biosciences SA announced that it expects to receive ?2.6 million in funding from Vester Finance	CI
13/04	Weekly Earnings Calendar: JPMorgan and Netflix in the US, LVMH and ASML in Europe,

20/25/20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
02/24/02	NFL Biosciences: Invest Securities reduces its target
15/24/15	NFL Biosciences: Invest Securities raises its target

NFL Biosciences Share Price

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news : NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Course Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

30/06	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
01/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU
25/05	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application	BU
11/05	NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101	BU
04/05	NFL Biosciences: International Scientific Community’s Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences	BU

30/06	NFL Biosciences valide la production industrielle du NFL-102 contre la tabagisme
30/06	NFL Biosciences annonce la fabrication avec succès d’un lot clinique GMP de NFL-102 et valide sa chaîne industrielle de production
17/06	NFL Biosciences : compte rendu de l’assemblée générale mixte du 17 juin 2026
13/06	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
02/06	Bourse : STMicro embrasse l'IA, BNP conteste un jugement et HPE on fire

1 day	+0.58%
1 week	+2.35%
1 month	-11.22%
3 months	-17.92%
6 months	-27.50%
Current year	-26.15%

1 week	0.83	0.92
1 month	0.8	0.99
Current year	0.8	1.85
1 year	0.8	1.85
3 years	0.8	3.31
5 years	0.55	5
10 years	0.55	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	17/10/2024
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	27/02/2023
Bruno Lafont CHM	Chairman	-	17/10/2024
Francis Ahner BRD	Director/Board Member	-	19/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	+0.58%	+2.35%	-23.01%	-66.28%	1.25Cr
ARGENX SE	+3.98%	+5.55%	+76.40%	+132.19%	5.62TCr
WUXI APPTEC CO., LTD.	-3.12%	+3.48%	+72.79%	+94.67%	5.54TCr
BIONTECH SE	+3.86%	+8.38%	-9.90%	-9.62%	2.38TCr
INSMED INCORPORATED	+4.30%	+6.82%	+13.60%	+428.91%	2.32TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+9.08%	+39.69%	-5.41%	1.81TCr
GENMAB A/S	+4.11%	+8.89%	+44.60%	-27.36%	1.68TCr
PHARMAESSENTIA CORPORATION	+2.57%	+16.74%	+171.12%	+355.99%	1.59TCr
EXELIXIS, INC.	+3.50%	+4.92%	+26.07%	+192.26%	1.36TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.91%	+15.12%	+37.72%	-	1.3TCr
Average	+2.32%	+7.77%	+44.91%	+121.70%	2.36TCr
Weighted average by Cap.	+1.89%	+6.91%	+56.94%	+134.94%

	2024	2025
Net sales	46 52.64 42.24 39.39 74.68 5.01T 75.94 508.59 197.1 2.46T 197.67 193.37 8.47T	188 215.15 172.64 160.99 305.21 20.48T 310.36 2.08T 805.55 10.05T 807.85 790.3 34.62T
Net income	-20.81L -23.81L -19.11L -17.82L -33.78L -23Cr -34.35L -2.3Cr -89.16L -11Cr -89.42L -87.47L -38Cr	-33.18L -37.97L -30.47L -28.41L -53.87L -36Cr -54.77L -3.67Cr -1.42Cr -18Cr -1.43Cr -1.39Cr -61Cr
Net Debt	-20.73L -23.72L -19.03L -17.75L -33.65L -23Cr -34.21L -2.29Cr -88.81L -11Cr -89.06L -87.12L -38Cr	-16.19L -18.53L -14.87L -13.87L -26.29L -18Cr -26.73L -1.79Cr -69.39L -8.65Cr -69.59L -68.08L -30Cr